Comparison
Octreotide vs. Retatrutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Metabolic
CAS no.
83150-76-9
2381089-83-2
Molecular weight
1019.24 g/mol
4731.6 g/mol
Half-life
1.7 h
144 h
Sequence
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Y-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSMechanism of action
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
5
of which in humans
4
4
Effects recorded
3
4
Open conflicts
0
0
Documented adverse events
2
2